MAP2K7 and melanoma: For instance, Cobimetinib, a marketed MEK inhibitor, was used in 12 of these trials, and the combination regimens resulted in longer progression-free survival than monotherapy using PD-L1 antibody or Cobimetinib in treating colorectal cancer and melanoma (109, 110).